Pasireotide LAR in patients with metastatic carcinoid tumors: Interim safety results from a randomized, multicenter phase I study

被引：0
|
作者：
Wolin, E. [1 ]
Kvols, L. [2 ]
Ezzat, S. [3 ]
Kocha, W. [4 ]
Van Cutsern, E. [5 ]
Schonherr, U. [6 ]
Fandi, A. [7 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[3] Univ Toronto, Ontario Canc Inst, Toronto, ON M5S 1A1, Canada
[4] London Reg Canc Ctr, London, ON N6A 4L6, Canada
[5] Univ Hosp Gasthuisberg, Digest Oncol Unit, B-3000 Leuven, Belgium
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [21] Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
    Sheppard, Michael
    Bronstein, Marcello D.
    Freda, Pamela
    Serri, Omar
    De Marinis, Laura
    Naves, Luciana
    Rozhinskaya, Liudmila
    Resendiz, Karina Hermosillo
    Ruffin, Matthieu
    Chen, YinMiao
    Colao, Annamaria
    PITUITARY, 2015, 18 (03) : 385 - 394
  • [22] Pharmacokinetic and Pharmacodynamic Analyses of Pasireotide LAR and Octreotide LAR Support the Efficacy Results of a Randomized, Double-Blind, Phase III Study in Patients with Medically Naive Acromegaly
    Shen, George
    Darstein, Christelle
    Resendiz, Karina Hermosillo
    Wang, Yanfeng
    Hu, Ke
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [23] Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
    Michael Sheppard
    Marcello D. Bronstein
    Pamela Freda
    Omar Serri
    Laura De Marinis
    Luciana Naves
    Liudmila Rozhinskaya
    Karina Hermosillo Reséndiz
    Matthieu Ruffin
    YinMiao Chen
    Annamaria Colao
    Pituitary, 2015, 18 : 385 - 394
  • [24] Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study
    Tahara, Shigeyuki
    Murakami, Mami
    Kaneko, Tomomi
    Shimatsu, Akira
    ENDOCRINE JOURNAL, 2017, 64 (07) : 735 - 747
  • [25] Effect of Hepatic Impairment on the Pharmacokinetics of Pasireotide (SOM230): Results From a Multicenter Phase I Study
    Horsmans, Yves
    Hu, Ke
    Ruffin, Matthieu
    Wang, Ying
    Song, Dongweon
    Bouillaud, Emmanuel
    Wang, Yanfeng
    Mazur, Dago
    Botha, Frans-Peter
    Heuman, Douglas M.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (04): : 552 - 558
  • [26] Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
    Wolin, Edward M.
    Jarzab, Barbara
    Eriksson, Barbro
    Walter, Thomas
    Toumpanakis, Christos
    Morse, Michael A.
    Tomassetti, Paola
    Weber, Matthias M.
    Fogelman, David R.
    Ramage, John
    Poon, Donald
    Gadbaw, Brian
    Li, Jiang
    Pasieka, Janice L.
    Mahamat, Abakar
    Swahn, Fredrik
    Newell-Price, John
    Mansoor, Wasat
    Oeberg, Kjell
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 5075 - 5086
  • [27] Updated safety, efficacy, and PK results from an open-label, multicenter, phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors
    Li, J.
    Cai, S.
    Deng, Y.
    Wu, X.
    Zheng, Z.
    Zhou, Y.
    Zhang, Y.
    Zhang, J.
    Tao, K.
    Cui, Y.
    Cao, H.
    Shen, K.
    Yu, J.
    Zhou, Y.
    Ren, W.
    Zhao, W.
    Wang, Y.
    Hu, J.
    Yang, J.
    Shen, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S207 - S207
  • [28] Final result of a phase I study of combination of pasireotide (SOM 230) LAR plus gemcitabine in metastatic pancreatic cancer (MPC)
    Suleiman, Yaman
    Springett, Gregory M.
    Siegel, Erin M.
    Shibata, David
    Fulp, William J.
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [29] Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
    Kvols, Larry K.
    Oberg, Kjell E.
    O'Dorisio, Thomas M.
    Mohideen, Pharis
    de Herder, Wouter W.
    Arnold, Rudolf
    Hu, Ke
    Zhang, Yilong
    Hughes, Gareth
    Anthony, Lowell
    Wiedenmann, Bertram
    ENDOCRINE-RELATED CANCER, 2012, 19 (05) : 657 - 666
  • [30] Multicenter Phase 2 Study of Nintedanib in Patients With Advanced Progressing Carcinoid Tumors
    Iyer, Renuka
    Konda, Bhavana
    Owen, Dwight
    Attwood, Kristopher
    Sarker, Suman
    Suffren, Sheryl-Ann
    Reidy, Diane
    Shah, Manisha
    PANCREAS, 2018, 47 (03) : 342 - 342
12345